Equities research analysts expect Insulet Co. (NASDAQ:PODD) to announce sales of $125.25 million for the current quarter, Zacks reports. Ten analysts have provided estimates for Insulet’s earnings, with the lowest sales estimate coming in at $124.20 million and the highest estimate coming in at $127.49 million. Insulet reported sales of $103.58 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 20.9%. The firm is scheduled to announce its next earnings results on Monday, February 26th.

According to Zacks, analysts expect that Insulet will report full year sales of $125.25 million for the current fiscal year, with estimates ranging from $447.00 million to $460.79 million. For the next financial year, analysts anticipate that the business will report sales of $557.17 million per share, with estimates ranging from $510.43 million to $588.51 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The firm had revenue of $121.80 million for the quarter, compared to the consensus estimate of $114.02 million. During the same quarter in the previous year, the firm posted ($0.05) EPS. The firm’s quarterly revenue was up 28.4% on a year-over-year basis.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Insulet from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Barclays boosted their target price on shares of Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 20th. UBS Group raised shares of Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday. Finally, Raymond James Financial raised shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research report on Monday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $62.53.

Insulet (PODD) traded up $0.75 on Thursday, hitting $75.83. 965,800 shares of the stock traded hands, compared to its average volume of 780,943. The company has a market cap of $4,410.00, a P/E ratio of -151.66 and a beta of 1.58. Insulet has a one year low of $38.43 and a one year high of $78.65. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42.

In other news, Director James C. Mullen purchased 2,500 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were acquired at an average price of $67.45 per share, for a total transaction of $168,625.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.60% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new stake in Insulet in the third quarter worth approximately $1,414,000. California Public Employees Retirement System grew its position in Insulet by 9.2% in the third quarter. California Public Employees Retirement System now owns 71,744 shares of the medical instruments supplier’s stock worth $3,952,000 after acquiring an additional 6,044 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in Insulet in the third quarter worth approximately $3,229,000. Cubist Systematic Strategies LLC bought a new stake in shares of Insulet during the 3rd quarter worth $406,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Insulet during the 3rd quarter worth $33,373,000.

TRADEMARK VIOLATION NOTICE: “$125.25 Million in Sales Expected for Insulet Co. (PODD) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/11/125-25-million-in-sales-expected-for-insulet-co-podd-this-quarter.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.